People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BioIntelliSense, Inc. | — | Other Health Care | Series C | $140.0M | $328.7M | 2018 |
| Seraph Biosciences, Inc. | — | Biotechnology | Series A | $10.0M | $253.9M | 2017 |
James Mault at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Mault on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Wang | 1 | 9 |
| Ronald Chwang | 1 | 7 |
| Larry Leisure | 1 | 6 |
| Dawn Owens | 1 | 4 |
| Steve Hess | 1 | 3 |
| Matthew Cullen | 1 | 3 |
| Michael Shields | 1 | 3 |
| Scott Merz | 1 | 3 |
| Alan R. Meeker | 1 | 1 |
| James R. Mault | 1 | 1 |
| John R. Driscoll | 1 | 1 |
| Lawrence R. Leisure | 1 | 1 |
| Steve R. Hess | 1 | 1 |
| Alan Meeker | 1 | 1 |
| Xinyaun Yu | 1 | 1 |
| Gary Loveman | 1 | 1 |
| Ahmad Nadeem Ishaque | 1 | 1 |
| Charles Shanley | 1 | 1 |
| Scott Nadeem Merz | 1 | 1 |
| James Nadeem Shanley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.